Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients

Effect of Short-term Dapagliflozin on Renal Function After Heart Catheterization or Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05225077

Enrollment

600

Registered

2022-02-04

Start date

2022-01-01

Completion date

2023-12-31

Last updated

2022-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Catheterization, Percutaneous Coronary Intervention, Renal Insufficiency, Chronic

Keywords

Sodium-Glucose Transporter 2 Inhibitors, Dapaglifozin, Chronic kidney disease

Brief summary

This study aim to investigate the protected effects of short-term use of dapagliflozin (administered within 3 days after procedure) in CKD patients after coronary angiography or percutaneous coronary intervention, as well as observed the incidence of CIN.

Interventions

DRUGDapagliflozin 10 MG [Farxiga]

Dapagliflozin 10 mg once a day for 1 month after CAG or PCI.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* Age\>18 years * Written informed consent * Glomerular Filtration Rate (GFR)≥ 30 ml/min/1.73m2 \[CKD stage G1-G3\] * Percutaneous coronary intervention in patients with NSTEMI, UA, STCD and asymptomatic patients

Exclusion criteria

* Active malignancy * Class I or equivalent indication for treatment with a SGLT2 inhibitor * Pregnancy or willing of pregnancy during the follow up period * Active urogenital infection * Diabetes mellitus type 1 * History of diabetic ketoacidosis * Cardiogenic shock * eGFR \< 29 ml/min/1.73m2

Design outcomes

Primary

Measure	Time frame	Description
Incidence of contrast induced nephropathy	48 hours	Serum creatinine (Scr) elevation of \>25% or \>0.5 mg/dl (44 μmol/l) from baseline within 48 hours

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026